Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1953 2
1954 1
1955 1
1956 2
1957 1
1958 1
1961 3
1962 2
1963 1
1966 1
1967 3
1969 3
1970 6
1971 2
1972 1
1974 1
1976 1
1977 1
1978 4
1979 1
1980 7
1981 3
1982 2
1983 5
1984 6
1985 8
1986 6
1987 8
1988 3
1989 4
1990 12
1991 10
1992 5
1993 13
1994 11
1995 11
1996 12
1997 15
1998 8
1999 21
2000 16
2001 19
2002 21
2003 21
2004 20
2005 28
2006 24
2007 30
2008 21
2009 25
2010 32
2011 26
2012 39
2013 32
2014 23
2015 20
2016 34
2017 42
2018 44
2019 44
2020 56
2021 58
2022 54
Text availability
Article attribute
Article type
Publication date

Search Results

847 results
Results by year
Filters applied: . Clear all
Page 1
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. Motzer R, et al. Among authors: eto m. N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13. N Engl J Med. 2021. PMID: 33616314 Clinical Trial.
Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape.
Takeuchi Y, Tanegashima T, Sato E, Irie T, Sai A, Itahashi K, Kumagai S, Tada Y, Togashi Y, Koyama S, Akbay EA, Karasaki T, Kataoka K, Funaki S, Shintani Y, Nagatomo I, Kida H, Ishii G, Miyoshi T, Aokage K, Kakimi K, Ogawa S, Okumura M, Eto M, Kumanogoh A, Tsuboi M, Nishikawa H. Takeuchi Y, et al. Among authors: eto m. Sci Immunol. 2021 Nov 12;6(65):eabc6424. doi: 10.1126/sciimmunol.abc6424. Epub 2021 Nov 12. Sci Immunol. 2021. PMID: 34767457
Fat Induces Glucose Metabolism in Nontransformed Liver Cells and Promotes Liver Tumorigenesis.
Broadfield LA, Duarte JAG, Schmieder R, Broekaert D, Veys K, Planque M, Vriens K, Karasawa Y, Napolitano F, Fujita S, Fujii M, Eto M, Holvoet B, Vangoitsenhoven R, Fernandez-Garcia J, Van Elsen J, Dehairs J, Zeng J, Dooley J, Rubio RA, van Pelt J, Grünewald TGP, Liston A, Mathieu C, Deroose CM, Swinnen JV, Lambrechts D, di Bernardo D, Kuroda S, De Bock K, Fendt SM. Broadfield LA, et al. Among authors: eto m. Cancer Res. 2021 Apr 15;81(8):1988-2001. doi: 10.1158/0008-5472.CAN-20-1954. Epub 2021 Mar 9. Cancer Res. 2021. PMID: 33687947 Free PMC article.
Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients.
Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Mizowaki T, Kamoto T, Kojima T, Kitamura H, Sugimoto M, Nishiyama H, Eto M; Japanese Urological Oncology Group (JUOG). Shiota M, et al. Among authors: eto m. Cancer Sci. 2021 Apr;112(4):1524-1533. doi: 10.1111/cas.14722. Epub 2021 Feb 13. Cancer Sci. 2021. PMID: 33159829 Free PMC article.
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial.
Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, Byun SS, Lee JL, Master V, Jin J, DeBenedetto R, Linke R, Casey M, Rosbrook B, Lechuga M, Valota O, Grande E, Quinn DI. Gross-Goupil M, et al. Among authors: eto m. Ann Oncol. 2018 Dec 1;29(12):2371-2378. doi: 10.1093/annonc/mdy454. Ann Oncol. 2018. PMID: 30346481 Free PMC article. Clinical Trial.
HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability.
Kawazu M, Ueno T, Saeki K, Sax N, Togashi Y, Kanaseki T, Chida K, Kishigami F, Sato K, Kojima S, Otsuka M, Kawazoe A, Nishinakamura H, Yuka M, Yamamoto Y, Yamashita K, Inoue S, Tanegashima T, Matsubara D, Tane K, Tanaka Y, Iinuma H, Hashiguchi Y, Hazama S, Khor SS, Tokunaga K, Tsuboi M, Niki T, Eto M, Shitara K, Torigoe T, Ishihara S, Aburatani H, Haeno H, Nishikawa H, Mano H. Kawazu M, et al. Among authors: eto m. Gastroenterology. 2022 Mar;162(3):799-812. doi: 10.1053/j.gastro.2021.10.010. Epub 2021 Oct 21. Gastroenterology. 2022. PMID: 34687740
Reply by Authors.
Kobayashi S, Cho B, Mutaguchi J, Inokuchi J, Tatsugami K, Hashizume M, Eto M. Kobayashi S, et al. Among authors: eto m. J Urol. 2020 Jul;204(1):156. doi: 10.1097/JU.0000000000000709.02. Epub 2020 Apr 23. J Urol. 2020. PMID: 32324094 No abstract available.
Le sous-type histologique des carcinomes tubulo-papillaires ne modifie pas les résultats oncologiques après néphrectomie partielle.
Bigot P, Bernhard J, Verhoest G, Flammand V, Gill I, Vuong N, Reix B, Suer E, Gökce I, Beauval J, Nouhaud F, Eto M, Baco E, Matsugasumi T, Chowaniec Y, Rigaud J, Lenormand C, Pfister C, Hetet J, Ploussard G, Roupret M, Léon P, El Bakri A, Larré S, Tillou X, Ingels A, Doerfler A. Bigot P, et al. Among authors: eto m. Prog Urol. 2015 Nov;25(13):799. doi: 10.1016/j.purol.2015.08.167. Prog Urol. 2015. PMID: 26544362 French. No abstract available.
847 results